COMPANY

Daré Bioscience

HQ: San Diego, CA source · darebioscience.com ↗ · West Coast

Keywords: women's health Contraception Vulvovaginal Atrophy Vasomotor Symptoms Bacterial Vaginosis Human Papilloma Virus High-risk Human Papillomavirus Infection Pre Term Birth Sexual Arousal Disorder Dysmenorrhea Primary Vulvar Atrophy Ovaprene Lopinavir / ritonavir Progesterone DARE-BV1

Location: San Diego, CA · source · Oct 13, 2026

Profile checked Oct 10, 2026

11Trials (company is sponsor)12NIH grants

Timeline

2026-09 Trial start Phase 1: Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert source ↗
Jul 17, 2026 Trial start Phase 2: A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) source ↗
Dec 19, 2023 Trial start Not phased (device or behavioral study): Contraceptive Efficacy Study of Ovaprene source ↗
May 19, 2023 Trial start Phase 1: A Study of Diclofenac Gel in Women With Primary Dysmenorrhea source ↗
May 13, 2023 Trial start Phase 1: Using Thermography to Assess the Affects of Sildenafil Cream, 3.6% source ↗
Apr 11, 2022 Trial start Phase 1/Phase 2: Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women source ↗
Nov 22, 2021 Trial start Phase 1/Phase 2: Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA source ↗
Nov 3, 2020 Trial start Phase 1: Pharmacokinetic Study of DARE-BV1 source ↗
Aug 18, 2020 Trial start 1: A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women source ↗
Jun 16, 2020 Trial start Phase 3: DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE) source ↗
May 23, 2018 Trial start Not phased (device or behavioral study): Safety and Acceptability Study of a Non-Hormonal Ring source ↗

Upcoming milestones

Apr 30, 2027 (ESTIMATED) · Not phased · Contraceptive Efficacy Study of Ovaprene · NCT06127199
2027-10 (ESTIMATED) · Phase 2 · A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV) · NCT07601074
2027-11 (ESTIMATED) · Phase 1 · Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert · NCT06668896

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 11

Record	Title	Phase	Status	Start	Primary completion
NCT06127199	Contraceptive Efficacy Study of Ovaprene	Not phased (device or behavioral study)	Recruiting	Dec 19, 2023	Apr 30, 2027 (estimated)
NCT07601074	A Study of the Preliminary Efficacy of DARE-HPV to Treat High-risk Persistent Human Papillomavirus (hrHPV)	Phase 2	Recruiting	Jul 17, 2026	2027-10 (estimated)
NCT06668896	Comparing the Pharmacokinetics of a Progesterone Ring Versus a Progesterone Vaginal Insert	Phase 1	Not yet recruiting	2026-09	2027-11 (estimated)
NCT05765487	Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%	Phase 1	Completed	May 13, 2023	Jan 26, 2024 (actual)
NCT05752526	A Study of Diclofenac Gel in Women With Primary Dysmenorrhea	Phase 1	Completed	May 19, 2023	Oct 10, 2023 (actual)
NCT05367973	Study of DARE-HRT1 Over 12 Weeks in Healthy PostMenopausal Women	Phase 1/Phase 2	Completed	Apr 11, 2022	Jan 9, 2023 (actual)
NCT05378269	Study of Intravaginal Tamoxifen in PostMenopausal Women With VVA	Phase 1/Phase 2	Completed	Nov 22, 2021	Dec 20, 2022 (actual)
NCT05418426	A Phase 1, Open-Label, Parallel Group Study to Evaluate the Pharmacokinetics and Safety of DARE-HRT1 in Healthy PostMenopausal Women	1	Completed	Aug 18, 2020	Apr 27, 2021 (actual)
NCT04370548	DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)	Phase 3	Completed	Jun 16, 2020	Nov 30, 2020 (actual)
NCT03598088	Safety and Acceptability Study of a Non-Hormonal Ring	Not phased (device or behavioral study)	Completed	May 23, 2018	Oct 17, 2019 (actual)
NCT05354050	Pharmacokinetic Study of DARE-BV1	Phase 1	Completed	Nov 3, 2020	Nov 18, 2020 (actual)

NIH awards 12

Annual award amounts. Total $8.1M.

Aug 25, 2026 NIH award 2R44HD113465-02A1 FY2026: $907,702 awarded for that fiscal year; activity R44 (SBIR); PI FRIEND, DAVID R; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. Therapeutic targeting of FKBP51 for the source ↗
May 20, 2026 NIH award 5R44AI188623-02 FY2026: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI THURMAN, ANDREA RIES; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. A first-in-class product for the cl source ↗
Dec 17, 2024 NIH award 5R44HD101169-03 FY2025: $1,016,258 awarded for that fiscal year; activity R44 (SBIR); PI FRIEND, DAVID R; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. A novel intravaginal ring technology fea source ↗
Dec 17, 2024 NIH award 1R44AI188623-01 FY2025: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI THURMAN, ANDREA RIES; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. A first-in-class product for the cl source ↗
Dec 11, 2023 NIH award 4R44HD101169-02 FY2024: $991,573 awarded for that fiscal year; activity R44 (SBIR); PI FRIEND, DAVID R; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. A novel intravaginal ring technology featu source ↗
Jul 28, 2023 NIH award 1R41HD113465-01 FY2023: $384,972 awarded for that fiscal year; activity R41 (STTR); PI FRIEND, DAVID R; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. Therapeutic targeting of FKBP51 for the pr source ↗
Mar 30, 2022 NIH award 1R43HD108820-01 FY2022: $249,336 awarded for that fiscal year; activity R43 (SBIR); PI FRIEND, DAVID R; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. Defining end-user preferences among US wom source ↗
Sep 21, 2021 NIH award 1R43HD107685-01 FY2021: $309,614 awarded for that fiscal year; activity R43 (SBIR); PI PROOS, ELIZABETH; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. Subcutaneous insertion and removal of a u source ↗
Aug 18, 2020 NIH award 1R44HD101169-01A1 FY2020: $299,696 awarded for that fiscal year; activity R44 (SBIR); PI FRIEND, DAVID R; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. A novel intravaginal ring technology fea source ↗
Mar 30, 2020 NIH award 5R44HD095724-03 FY2020: $730,722 awarded for that fiscal year; activity R44 (SBIR); PI MAUCK, CHRISTINE; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. Safety, and acceptability of a non-hormon source ↗
Mar 6, 2019 NIH award 4R44HD095724-02 FY2019: $982,851 awarded for that fiscal year; activity R44 (SBIR); PI MAUCK, CHRISTINE; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. Safety, and acceptability of a non-hormon source ↗
Apr 27, 2018 NIH award 1R44HD095724-01 FY2018: $224,655 awarded for that fiscal year; activity R44 (SBIR); PI MAUCK, CHRISTINE; recipient as written: DARE BIOSCIENCE, INC., San Diego, CA. Safety, and acceptability of a non-hormon source ↗